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High-Density Lipoproteins
From Function to Therapy*
Chunyu Zheng, SCD, Masanori Aikawa, MD, PHD
Boston, Massachusetts
The substantial residual cardiovascular events present in
statin-treated patients provide a challenge to researchers in
the cardiovascular field to develop additional therapeutic
approaches. In cardiovascular disease (CVD) epidemiology,
few associations are as consistent and enduring as the
inverse association between high-density lipoprotein cho-
lesterol (HDL-C) levels and risk for coronary artery disease
(1). Observational studies have shown that each 1-mg/dl
ecrease in HDL-C concentration is associated with a 2% to
% increased risk of CVD (2). This strong inverse relationship
as stimulated interest in determining mechanisms and opti-
al management of low levels of HDL-C (3,4).
See page 2372
Clinical and pre-clinical evidence has established that
lowering of low-density lipoprotein cholesterol (LDL-C)
levels reduces vascular inflammation and activation and
prevents the onset of acute thrombotic complications of
atherosclerosis (5,6). However, in contrast to observational
studies that have consistently identified HDL-C as a potent
cardioprotective factor, interventional CVD trials evaluating
HDL have so far been discouraging. Phase III trials with
torcetrapib and dalcetrapib, a class of drugs that elevate the
concentration of large, mature HDL through cholesteryl
ester transfer protein (CETP) inhibition, were terminated
prematurely due to excess adverse events (7) and futility (8).
Another study, AIM-HIGH (Atherothrombosis Interven-
tion in Metabolic Syndrome With Low HDL/High Trig-
lycerides: Impact on Global Health Outcomes), which was
conducted to validate the benefit of raising HDL-C levels
through extended-release niacin in a group of high-risk
patients with managed low LDL-C levels, failed to show
any incremental clinical benefit, although the difference in
HDL-C values between the niacin and placebo groups was
unexpectedly small, only 5.0 mg/dl (9). In addition, recent
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netic variants of apolipoprotein AI (apoAI), lecithin-
cholesterol acyltransferase (LCAT), and endothelial lipase
apparently exhibited isolated effects on HDL-C level failed
to show a causal relationship between genetically deter-
mined HDL-C level and predicted CVD risk, even when
HDL-C level and risk were strongly related in the back-
ground population (10). Should we give up on HDL? Or
should we establish a new rationale behind HDL-raising
therapy?
The dichotomy of findings from observational studies
and randomized trials emphasizes the complexity of HDL
in vascular disease. It is becoming increasingly evident that
the “quality” of HDL matters as much as its “quantity.” The
HDL-C blood levels do not necessarily capture the diverse
atheroprotective functions of the heterogeneous HDL pop-
ulations and may not be a reliable surrogate for causative
biological processes through which HDL protects against
atherosclerotic plaque development.
HDL may exert protective effects against CVD through
multiple mechanisms. The most popular view is that HDL
elicits cholesterol efflux from cholesterol ester–enriched
macrophage foam cells in atheromata and transfers the excess
cholesterol ester to the liver for excretion (11), a process termed
reverse cholesterol transport (RCT) (Fig. 1). In addition to
removing excess plaque lipids, HDL exhibits anti-
inflammatory, antithrombotic, and antioxidant effects and
improves endothelial function (4,11), which could also
contribute to reduction in atherosclerosis. Accumulating
evidence suggests that HDL may lose its atheroprotective
functions in chronic and inflammatory diseases and become
dysfunctional (12). HDL may even gain atherogenic agents,
as summarized in Figure 2. For example, the concentration
of HDL that contains apoCIII may directly (harmfully)
associate with CVD (13). ApoCIII has proinflammatory,
proatherogenic effects on cells that participate in atheroscle-
rosis (14). HDL can acquire apoCIII during secretion by
the liver or intestine or by transfer from very low-density
lipoprotein while in the circulation (15).
Low HDL-C level represents a major lipid abnormality
and CVD risk in patients with chronic renal disease (16).
This is particularly important because lowering LDL-C
levels with statins has diminished benefits in end-stage renal
disease (ESRD) (17). In this issue of the Journal, Yamamoto
et al. (18) reported that HDL from patients with ESRD
exhibited hallmarks of impaired atheroprotective functions:
markedly reduced cholesterol efflux capacity, attenuated
antichemotactic ability, and increased proinflammatory ef-
fects. HDL from patients undergoing statin therapy, al-
though less proinflammatory, did not show improved cho-
lesterol efflux function, suggesting independence among
different atheroprotective functions of HDL (18). This
interesting clinical study is consistent with recent reports of
HDL proteome and lipidome. HDL from ESRD carries a
distinct protein cargo, evidenced by enrichment of acute-
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Functionality studies like these are crucial for developing
effective HDL therapeutics to prevent/treat CVD. It is
apparent that not all HDL particles are created equal, and
no doubt the “method” of raising HDL levels has everything
to do with any clinical benefit conferred. HDL functionality
assessment, in addition to raising HDL particle concentra-
tion (or HDL-C), would be a crucial part of any future drug
development. Various functional aspects of HDL, including
the following issues, deserve attention.
1. CETP inhibition remains a viable option to raise
HDL-C and lower LDL-C levels to reduce CVD risk.
Studies to date have not supported an adverse effect of
CETP inhibition on HDL function. The hypothetical
benefit on atherosclerosis was offset by a molecule-
specific off-target toxicity effect of torcetrapib (20),
which was not shared by other CETP inhibitors, such
as anacetrapib and evacetrapib (21,22). On the other
hand, dalcetrapib, a partial CETP inhibitor, in con-
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and may be suitable for chronic use (26).
. Identification of HDL components that directly affect its
atheroprotective functions. In addition to apoAI and
apoAII, HDL carries more than 30 other proteins (19),
and some of them are involved in lipid metabolism and
vascular inflammation, including apoCIII, apoLI, and
paraoxonase 1. These HDL modulators may be potential
targets for drug development. They may also be used as
biomarkers to gauge HDL functionality.
. RCT quantification and metrics of HDL “quality.”
There is an urgent need for effective investigational and
clinical tools that measure HDL quality as well as
quantity to guide drug development and evaluation
through pre-clinical and early clinical phases before
embarking on expensive large-scale CVD outcome trials.
It was recently reported that the cholesterol efflux capac-
ity of HDL, calculated from ex vivo cultured macro-
phages, has a strong inverse association with regression
of coronary artery disease independent of plasma
HDL-C levels in a CVD imaging trial (27). Several
laboratories are also developing methods for quantifying
RCT in humans using stable isotopes. In addition to
RCT, similarly principled metrics (28), with their anti-
inflammatory, antithrombotic, and antioxidant functions
Figure 2 Functional Versus Dysfunctional HDL
High-density lipoprotein (HDL) can become dysfunctional after exposure to an infla
tration represent markers of functional or dysfunctional HDL. The loss or modifica
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ment of HDL’s atheroprotective functions.
In summary, low levels of HDL-C are associated with
ncreased cardiovascular risk, even among patients with
ggressive statin regimens, which leads to the recommen-
ation of raising HDL levels as a rational target. However,
t is becoming increasingly apparent that not all HDL
articles are created equal and that the “quality” of HDL
atters as much as its “quantity.” Future research should
xplore the most efficient methods of improving HDL
uality, measuring functions of raised HDL levels by new
herapies, as well as designing metrics of HDL multifaceted
theroprotective functions.
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